Menu Search
Equities

medmix AG

8KQ:BRN

medmix AG

Actions
  • Price (CHF)9.95
  • Today's Change0.09 / 0.91%
  • Shares traded94.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CHFIncome statement in CHFView more

Year on year medmix AG's net income fell -97.41% from 11.60m to 300.00k despite relatively flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 63.24% to 67.59%.
Gross margin32.58%
Net profit margin-0.21%
Operating margin3.00%
Return on assets-0.10%
Return on equity-0.38%
Return on investment-0.12%
More ▼

Cash flow in CHFView more

In 2023, cash reserves at medmix AG fell by 182.90m. However, the company earned 56.10m from its operations for a Cash Flow Margin of 11.53%. In addition the company used 80.60m on investing activities and also paid 153.80m in financing cash flows.
Cash flow per share1.36
Price/Cash flow per share7.16
Book value per share11.30
Tangible book value per share1.53
More ▼

Balance sheet in CHFView more

medmix AG has a Debt to Total Capital ratio of 43.61%, a lower figure than the previous year's 62.97%.
Current ratio1.48
Quick ratio1.06
Total debt/total equity0.7895
Total debt/total capital0.4361
More ▼

Growth rates in CHF

SmartText is unavailable
EPS growth(5 years)-65.66
EPS (TTM) vs
TTM 1 year ago		57.80
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.